Camilla Chong, MD, Chief Medical Officer of InflaRx, commented: "We are pleased to have started our Phase 2a trial for INF904 ...

This is the last edition of Yield Outlook in 2024. The editorial team wishes our readers a Merry Christmas and a happy and prosperous New Year.

A drug that combines an atypical antipsychotic and an SSRI is under FDA review, and if approved will be the first ...

SPEARFISH — The first phase of the Colorado Boulevard sanitary sewer upsizing project in Spearfish is complete. On Monday, ...

The American economy grew at a healthy 3.1% annual clip from July through September, propelled by vigorous consumer spending ...

AnaptysBio's rosnilimab faces significant competition and uncertainty. See why ANAB stock's future hinges on Feb 2025 Phase ...

According to the company, its Phase 1/2 CLARA trial of AURN001 for corneal edema demonstrated significant dose-dependent ...

Viatris Inc. (NASDAQ: VTRS) today announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of cenerimod in adults with moderate-to-severe systemic lupus ...

Keros Therapeutics is a clinical-stage biopharmaceutical company focusing on rare and hematological diseases. Read why I rate KROS stock a Hold now.

The United Kingdom’s Competition and Markets Authority (CMA) will, in the new year, launch a review of its approach to merger ...

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...